HGH Fragment 176-191
HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.
Mechanism of Action
Mimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors.
Dosage Overview
Dose Range
250 mcg – 500 mcg
Route
subcutaneous
Frequency
2x daily
Cycle Length
12–16 weeks
Reconstitution
Typical Dosage (Research)
Typical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio.
Subcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection.
Considerations for Men & Women
Women: May be more responsive at lower doses given women's generally higher GH sensitivity. No established pregnancy safety data — avoid during pregnancy and breastfeeding.
Men: Standard research protocols apply. Often stacked with other peptides in body composition protocols. No sex-specific dose adjustments established.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 2,500 mcg/ml
Volume to inject: 0.10 ml
Syringe units (U-100): 10.0 units
Pre-filled with HGH Fragment 176-191 defaults. Adjust values as needed.
Side Effects & Risks
Generally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly.
Limited human research data. Not FDA approved. Quality and purity vary significantly between sources.
Who Uses HGH Fragment 176-191
Those seeking targeted fat loss without muscle-building effects, individuals in cutting phases, those wanting GH fat-loss benefits without growth effects.
Similar Peptides
View All Alternatives →Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.